|
gptkbp:instanceOf
|
gptkb:drug
gene therapy
|
|
gptkbp:administeredAfter
|
lymphodepleting chemotherapy
|
|
gptkbp:administeredBy
|
specialized treatment centers
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2017-10-18
|
|
gptkbp:ATCCode
|
L01XL08
|
|
gptkbp:blackBoxWarning
|
yes
|
|
gptkbp:brand
|
gptkb:Yescarta
|
|
gptkbp:cost
|
high
|
|
gptkbp:developer
|
gptkb:Kite_Pharma
|
|
gptkbp:drugClass
|
immunotherapy
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
axicabtagene ciloleucel
|
|
gptkbp:indication
|
gptkb:primary_mediastinal_large_B-cell_lymphoma
relapsed or refractory large B-cell lymphoma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Kite_Pharma
|
|
gptkbp:marketedAs
|
gptkb:Gilead_Sciences
|
|
gptkbp:mechanismOfAction
|
CD19-directed genetically modified autologous T cell immunotherapy
|
|
gptkbp:pregnancyCategory
|
not established
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
cytokine release syndrome
neurological toxicities
|
|
gptkbp:source
|
autologous T cells
|
|
gptkbp:storage
|
cryopreserved
|
|
gptkbp:target
|
gptkb:CD19
|
|
gptkbp:bfsParent
|
gptkb:CD19
gptkb:Yescarta
|
|
gptkbp:bfsLayer
|
6
|